Navigation Links
Out-of-Pocket Costs Limit Access to Arthritis Drugs
Date:5/25/2010

Insurance woes keep rheumatoid arthritis patients from biologic meds, study finds

TUESDAY, May 25 (HealthDay News) -- Effective but expensive biologic drugs are less likely to be used by American rheumatoid arthritis patients who have inadequate health insurance or are struggling with medical co-payments, a new study reveals.

Biologics, which alter immune system function, are sometimes used to treat rheumatoid arthritis when more conventional treatments don't work.

"Our study showed that out-of-pocket cost is a concern in the decision to initiate these drugs," lead author Pinar Karaca-Mandic, an assistant professor in the School of Public Health at the University of Minnesota, said in a news release. "If higher cost-sharing forces people away from preferred, effective therapy, they could end up with higher complication and medical costs."

Karaca-Mandic and her research team released their findings online May 24 in advance of publication in an upcoming print issue of the journal Health Services Research.

The cautionary note stems from an analysis of health insurance data gleaned from 35 large, private U.S. employers from 2000 to 2005.

From a pool of more than 8,500 newly diagnosed rheumatoid arthritis patients, the authors found that 2,066 of them had used one of the three most commonly prescribed biotech drugs: etanercept (Enbrel), adalimumab (Humira) or infliximab (Remicade).

However, the team found that the likelihood of taking any of these drugs was lower among patients who had to pay more for them. What's more, unmanageable costs also raised the risk that those who started a biotech regimen would end up abandoning the treatment.

Rheumatoid arthritis patients from families already burdened with high health costs overall were less than 50 percent as likely to begin a biotech regimen in the first place, the authors found, although those who did so anyway were not more likely to stop once they started.

"Families have a separate budget for health care, and may not be flexible around expanding it," noted Karaca-Mandic. "If other members are getting sick, they may want to draw resources away from the rheumatoid arthritis patient."

More information

For more on rheumatoid arthritis, visit the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases.



-- Alan Mozes



SOURCE: Health Behavior News Service, news release, May 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. National Patient Advocate Foundation Delivers Constituent Cases to White House Health Summit Participants to Urge Elimination of Pre-Existing Conditions, Annual/Lifetime Limits and Capping Out-of-Pocket Expenses
2. Corporate health program reduces employee CVD medical, hospital costs
3. Insightful Case Study Details How Electronic Payment Exchange Saved a Global Firm More Than $3 Million in PCI-Related Costs
4. Medical Devices Driving Up Heart Care Costs
5. New Healthcare Book Helps Families Navigate Rising Healthcare Costs and Decreasing Coverage
6. Alzheimers Costs Could Explode by Mid-Century
7. Study shows costs and benefits of testosterone in birds
8. U.S. Cancer Costs Double in Two Decades
9. Medical costs of cancer have nearly doubled over the past 2 decades
10. PCMA: New Legislation Would Increase Prescription Drug Costs, Limit Access
11. Urgent Nuclear Stress Test Lab Costs Reductions for Physician Practices in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the safety of your ... drownings during the summer. While most of us assume this type of accident will ... Very few people are taking the time to learn how to respond effectively or ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... announce the ATA 2017 President’s Awards recipients, comprised of organizations and individuals ... delivery. , The ATA 2017 President’s Awards recognize individuals and organizations ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: